Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lagrange Oncology Associates
mi
from
La Grange, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lagrange Oncology Associates
mi
from
La Grange, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
West Suburban Center for Cancer Care
mi
from
River Forest, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
West Suburban Center for Cancer Care
mi
from
River Forest, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Fort Wayne Medical Oncology and Hematology, Incorporated
mi
from
Fort Wayne, IN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Fort Wayne Medical Oncology and Hematology, Incorporated
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Baptist Hospital East - Louisville
mi
from
Louisville, KY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Baptist Hospital East - Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
UMASS Memorial Cancer Center - University Campus
mi
from
Worcester, MA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
UMASS Memorial Cancer Center - University Campus
mi
from
Worcester, MA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
mi
from
Saint Joseph, MI
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Missouri Baptist Cancer Center
mi
from
Saint Louis, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Missouri Baptist Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Las Vegas
mi
from
Las Vegas, NV
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Las Vegas
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
New Hampshire Oncology - Hematology, PA - Hooksett
mi
from
Hooksett, NH
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
New Hampshire Oncology - Hematology, PA - Hooksett
mi
from
Hooksett, NH
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Cancer Institute of New Jersey at the Cooper University Hospital
mi
from
Camden, NJ
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Cancer Institute of New Jersey at the Cooper University Hospital
mi
from
Camden, NJ
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
East Syracuse, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Elmhurst Hospital Center
mi
from
Elmhurst, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Elmhurst Hospital Center
mi
from
Elmhurst, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Queens Cancer Center of Queens Hospital
mi
from
Jamaica, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Queens Cancer Center of Queens Hospital
mi
from
Jamaica, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Mount Sinai Hospital
mi
from
New York, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Asheville
mi
from
Asheville, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Asheville
mi
from
Asheville, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
NorthEast Oncology Associates - Concord
mi
from
Concord, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
NorthEast Oncology Associates - Concord
mi
from
Concord, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Cape Fear Valley Medical Center
mi
from
Fayetteville, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Cape Fear Valley Medical Center
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lenoir Memorial Cancer Center
mi
from
Kinston, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lenoir Memorial Cancer Center
mi
from
Kinston, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Comprehensive Cancer Center at Moore Regional Hospital
mi
from
Pinehurst, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Comprehensive Cancer Center at Moore Regional Hospital
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Zimmer Cancer Center at New Hanover Regional Medical Center
mi
from
Wilmington, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Zimmer Cancer Center at New Hanover Regional Medical Center
mi
from
Wilmington, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials